NewBridge Signs License, Supply Agreement With Axcan

NewBridge has entered into a license and supply agreement with Axcan for Pylera, a patented 3-in-1 capsule therapy for the eradication of Helicobacter pylori.

Each Pylera capsule contains bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride.

According to the agreement, NewBridge is entitled to obtain exclusive rights in certain markets, where it obtains required regulatory approvals and launches the product. The product is expected to be launched in the fourth quarter of 2010.

Nicholas Franco, senior vice president of International Commercial Operations at Axcan, said: We are happy to be partnering with NewBridge which will enable Axcan’s Pylera to be launched in rapidly growing markets in which NewBridge has expertise.